🔎 Trials Near Me

Home › Leucemia mieloide acuta › Ohio › Columbus

Studi clinici su Leucemia mieloide acuta a Columbus, OH

35 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Columbus e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 60 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

In reclutamentoStudio osservazionaleVolontari sani benvenuti
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • e altri 8
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

In reclutamentoFase 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT03874052

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

In reclutamentoFase 3
  • Nationwide Children's Hospital, Columbus
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

In reclutamentoFase 1/2
  • Ohio State University, Columbus
30 Days · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

In reclutamentoFase 1
  • Ohio State University, The James Comprehensive Cancer, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06846606

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

In reclutamentoFase 1/2
  • The Ohio Sate University, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06969430

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

In reclutamentoFase 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età da 18 a 75 · Tutti i sessi · Aggiornato il 9 set 2026 · NCT04049539

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

In reclutamentoStudio osservazionale
  • OhioHealth Research Institute, Columbus
Età 0 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

In reclutamentoFase 3
  • US-Colombus OH-OSU, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

In reclutamentoFase 3
  • US-Colombus OH-OSU, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07223814

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06930352

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

In reclutamentoFase 1
  • Ohio State University, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06533761

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

In reclutamentoFase 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT05886049

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

In reclutamentoFase 3
  • Nationwide Children's Hospital, Columbus
29 Days – 21 Years · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

In reclutamentoFase 3
  • Ohio State University, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT07007312

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

In reclutamentoStudio osservazionale
  • Nationwide Children's Hospital, Columbus
  • The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

In reclutamentoFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT05401097

Ivosidenib as Post-HSCT Maintenance for AML

In reclutamentoFase 2
  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Età da 18 a 75 · Tutti i sessi · Aggiornato il 18 giu 2026 · NCT06707493

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

In reclutamentoFase 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 mag 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

In reclutamentoFase 1
  • The Ohio State University, Columbus
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

In reclutamentoFase 2/3
  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 apr 2026 · NCT04256317

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

In reclutamentoFase 1
  • Ohio State University Medical Center, Columbus
Età da 18 a 65 · Tutti i sessi · Aggiornato il 25 mar 2026 · NCT03533816

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

In reclutamentoFase 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555

Ziftomenib Maintenance Post Allo-HCT

In reclutamentoFase 1
  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 mar 2026 · NCT06440135

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

In reclutamentoFase 1
  • The James Cancer Hospital and Solove Research Institute, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

In reclutamentoFase 1
  • The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2025 · NCT06501196

HPC Offered for PRESERVE Expansion

In reclutamentoStudio osservazionale
  • The Ohio State University Medical Center, Columbus
Età da 12 a 80 · Tutti i sessi · Aggiornato il 28 ago 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

In reclutamentoFase 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

In reclutamentoVolontari sani benvenuti
  • Ohio State University, Columbus
Età da 18 a 120 · Tutti i sessi · Aggiornato il 25 lug 2025 · NCT05237258

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

In reclutamentoFase 1/2
  • Nationwide Children's Hospital, Columbus
Età da 1 a 24 · Tutti i sessi · Aggiornato il 4 nov 2024 · NCT05503134

Studi su Leucemia mieloide acuta in altre città

Altri studi a Columbus

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.